Credit Suisse’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $879K | Hold |
41,704
| – | – | ﹤0.01% | 2341 |
|
|
2023
Q4 | $749K | Buy |
41,704
+4,713
| +13% | +$83K | ﹤0.01% | 2524 |
|
|
2023
Q3 | $609K | Sell |
36,991
-8,067
| -18% | -$146K | ﹤0.01% | 2576 |
|
|
2023
Q2 | $901K | Buy |
45,058
+11,954
| +36% | +$230K | ﹤0.01% | 2450 |
|
|
2023
Q1 | $626K | Buy |
33,104
+9
| +0% | +$199 | ﹤0.01% | 2618 |
|
|
2022
Q4 | $751K | Sell |
33,095
-8,530
| -20% | -$193K | ﹤0.01% | 2540 |
|
|
2022
Q3 | $1.1M | Buy |
41,625
+7,820
| +23% | +$232K | ﹤0.01% | 2259 |
|
|
2022
Q2 | $835K | Sell |
33,805
-4,232
| -11% | -$106K | ﹤0.01% | 2510 |
|
|
2022
Q1 | $1.26M | Buy |
38,037
+1,745
| +5% | +$48.5K | ﹤0.01% | 2397 |
|
|
2021
Q4 | $1.19M | Buy |
36,292
+1,766
| +5% | +$60.1K | ﹤0.01% | 3185 |
|
|
2021
Q3 | $1.45M | Sell |
34,526
-4,066
| -11% | -$146K | ﹤0.01% | 3057 |
|
|
2021
Q2 | $1.5M | Sell |
38,592
-817
| -2% | -$29.2K | ﹤0.01% | 3074 |
|
|
2021
Q1 | $1.35M | Sell |
39,409
-20,328
| -34% | -$867K | ﹤0.01% | 3104 |
|
|
2020
Q4 | $2.71M | Sell |
59,737
-467,506
| -89% | -$16.3M | ﹤0.01% | 2601 |
|
|
2020
Q3 | $14.5M | Sell |
527,243
-9,755
| -2% | -$318K | 0.01% | 1178 |
|
|
2020
Q2 | $19.8M | Buy |
536,998
+34,432
| +7% | +$1.28M | 0.01% | 955 |
|
|
2020
Q1 | $16.3M | Sell |
502,566
-5,681
| -1% | -$237K | 0.01% | 931 |
|
|
2019
Q4 | $20.8M | Buy |
508,247
+20,393
| +4% | +$806K | 0.02% | 991 |
|
|
2019
Q3 | $17.4M | Sell |
487,854
-6,661
| -1% | -$270K | 0.01% | 1003 |
|
|
2019
Q2 | $25.4M | Sell |
494,515
-776
| -0.2% | -$38.7K | 0.02% | 789 |
|
|
2019
Q1 | $28.4M | Sell |
495,291
-15,993
| -3% | -$792K | 0.03% | 668 |
|
|
2018
Q4 | $21.4M | Buy |
511,284
+66,373
| +15% | +$3.89M | 0.02% | 761 |
|
|
2018
Q3 | $33.6M | Buy |
444,911
+106,333
| +31% | +$7.66M | 0.03% | 593 |
|
|
2018
Q2 | $24.3M | Buy |
338,578
+308,023
| +1,008% | +$14.7M | 0.02% | 732 |
|
|
2018
Q1 | $912K | Buy |
30,555
+2,618
| +9% | +$76.2K | ﹤0.01% | 3028 |
|
|
2017
Q4 | $930K | Sell |
27,937
-6,727
| -19% | -$203K | ﹤0.01% | 3050 |
|
|
2017
Q3 | $1.14M | Buy |
34,664
+6,435
| +23% | +$145K | ﹤0.01% | 2999 |
|
|
2017
Q2 | $557K | Buy |
28,229
+8,295
| +42% | +$161K | ﹤0.01% | 3081 |
|
|
2017
Q1 | $384K | Sell |
19,934
-13,253
| -40% | -$256K | ﹤0.01% | 3432 |
|
|
2016
Q4 | $616K | Buy |
+33,187
| New | +$634K | ﹤0.01% | 3328 |
|
|
2016
Q3 | – | Sell |
-11,390
| Closed | -$91K | – | 4227 |
|
|
2016
Q2 | $91K | Buy |
+11,390
| New | +$126K | ﹤0.01% | 4074 |
|
Other funds holding RGNX
RG
APM
ACM
Credit Suisse's RGNX Position: Q1 2024 in Review
Credit Suisse held its Regenxbio (RGNX) position steady in Q1 2024 at 41,704 shares worth $879K. The position accounts for ﹤0.01% of the portfolio, ranked #2341.
Credit Suisse first reported a position in RGNX in Q2 2016 and has held it in 31 quarters since. The position peaked at $33.6M in Q3 2018. 188 funds tracked by Wall St. Rank hold RGNX as of Q1 2024.
- Credit Suisse held 41,704 shares of Regenxbio worth $879K as of Q1 2024.
- Credit Suisse left its Regenxbio share count unchanged in Q1 2024.
- Regenxbio made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2341 holding.
- Credit Suisse first reported a position in Regenxbio in Q2 2016 and has held it in 31 quarters since.
- Credit Suisse's Regenxbio position peaked at $33.6M in Q3 2018.
- 188 funds tracked by Wall St. Rank held Regenxbio as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.